The observed binding interactions can be exploited in the design of improved toxin binding inhibitors.
For assessing the specificity of protein kinases for inhibitors, Ambit applied ATP site-dependent competition binding assays that directly and quantitatively measure the binding of inhibitors to the ATP binding site of kinases.
A protective monoclonal antibody C3.1 binds this antigen and exhibits a unique binding profile where di and trisaccharides are the most potent inhibitors, while the intrinsic affinities of tetrasaccharide and larger oligomers dramatically decrease with increasing chain length.
The "front door" is the actual substrate-binding site accommodating the arginine side chain residue and derived inhibitors, while the "back door" provides solvent access through a highly polar tunnel connected to the base of the active site.
We and others (Barkovich et al, 2012; Vivanco et al, 2012) have found that ECD and KD mutations cause distinct shifts in the conformational equilibrium of the KD, such that each type of mutation favours binding of one type of ATP competitive inhibitors, while limiting the binding and thereby the effectiveness of others.
In the present study, Tat±morphine increased IkBα phosphorylation, the rate of p65 translocation into the nucleus, and NF-κB binding by EMSA, while the NF-κB inhibitor parthenolide eliminated cytokine release in Tat±morphine treated astrocytes.
However, the binding of the inhibitor affects the binding of the substrate, and vice versa.
Upon inhibitor binding, the binding-site residues undergo subtle structural rearrangement.
The rapid, reversible inhibitors are relatively weak inhibitors of AA oxygenation, whereas the slow, tight-binding inhibitors are more potent.
A related measure of similarity that also uses inhibitor binding data is the correlations of inhibitor binding profiles between pairs of kinases.
